NewAmsterdam Pharma N.V. (NAMS) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 30.6% versus a loss of 35.3%. Over five years, TRVI leads with a +894.2% price change compared with +117.2% for NAMS. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.47 billion vs $1.82 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAMS | TRVI |
|---|---|---|
| Share price | $21.15 | $12.77 |
| Market cap | $2.47B | $1.82B |
| 1-day change | -0.52% | -0.43% |
| YTD return | -39.40% | +2.44% |
| 1-year return | -35.30% | +30.60% |
| 5-year return | +117.16% | +894.19% |
| EPS (TTM) | $-2.16 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $22.50M | — |
| Revenue growth (YoY) | -50.61% | — |
| Net income (latest FY) | $-203.82M | $-42.76M |
| Operating margin | -1002.90% | — |
| Net margin | -905.74% | — |
| 52-week high | $42.21 | $20.22 |
| 52-week low | $20.91 | $9.28 |
| Distance from 52-week high | -49.89% | -36.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +134.75% | +120.67% |
| Average volume | 1.36M | 2.03M |
| Shares outstanding | 116.90M | 142.48M |
| Employees | 100 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRVI has outperformed NAMS by 65.9 percentage points over the past year.
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
NAMS vs TRVI FAQ
Which is bigger, NewAmsterdam Pharma N.V. or Trevi Therapeutics?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.47B compared with $1.82B for Trevi Therapeutics (TRVI).
Which stock has performed better over the past year, NAMS or TRVI?
TRVI returned +30.60% over the past 12 months, compared with -35.30% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are NewAmsterdam Pharma N.V. and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.